Nutriband Inc
NTRB7.115USD
-0.275-3.72%
Horário de mercado （ET）Cotações atrasadas em 15 min
78.80MValor de mercado
PerdaP/L TTM
Mais detalhes de Nutriband Inc Empresa
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Informações da empresa
Código da empresaNTRB
Nome da EmpresaNutriband Inc
Data de listagemJun 20, 2017
CEOMr. Gareth Sheridan
Número de funcionários- -
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 20
Endereço121 S Orange Ave Ste 1500
CidadeORLANDO
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal32801-3241
Telefone14073776695
Sitehttps://nutriband.com/
Código da empresaNTRB
Data de listagemJun 20, 2017
CEOMr. Gareth Sheridan
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Gareth Sheridan
Mr. Gareth Sheridan
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
1.76M
--
Mr. Serguei Melnik
Mr. Serguei Melnik
Chairman of the Board, President, Secretary
Chairman of the Board, President, Secretary
820.42K
--
Mr. Gerald Goodman
Mr. Gerald Goodman
Chief Financial Officer
Chief Financial Officer
86.33K
--
Dr. Jeff Patrick, Pharm.D.
Dr. Jeff Patrick, Pharm.D.
Chief Scientific Officer
Chief Scientific Officer
36.61K
--
Mr. Mark Hamilton
Mr. Mark Hamilton
Independent Director
Independent Director
17.21K
--
Mr. Radu Bujoreanu
Mr. Radu Bujoreanu
Independent Director
Independent Director
15.75K
--
Ms. Irina Gram
Ms. Irina Gram
Independent Director
Independent Director
1.17K
--
Mr. Sergei Glinka
Mr. Sergei Glinka
Independent Director
Independent Director
--
--
Prof. Dr. Stefani C. Mancas
Prof. Dr. Stefani C. Mancas
Independent Director
Independent Director
--
--
Dr. Alan Smith, Ph.D.
Dr. Alan Smith, Ph.D.
Chief Operating Officer, President of 4P Therapeutics
Chief Operating Officer, President of 4P Therapeutics
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Gareth Sheridan
Mr. Gareth Sheridan
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
1.76M
--
Mr. Serguei Melnik
Mr. Serguei Melnik
Chairman of the Board, President, Secretary
Chairman of the Board, President, Secretary
820.42K
--
Mr. Gerald Goodman
Mr. Gerald Goodman
Chief Financial Officer
Chief Financial Officer
86.33K
--
Dr. Jeff Patrick, Pharm.D.
Dr. Jeff Patrick, Pharm.D.
Chief Scientific Officer
Chief Scientific Officer
36.61K
--
Mr. Mark Hamilton
Mr. Mark Hamilton
Independent Director
Independent Director
17.21K
--
Mr. Radu Bujoreanu
Mr. Radu Bujoreanu
Independent Director
Independent Director
15.75K
--
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2026Q1
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2021
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
Sale of goods
667.43K
0.00%
Services
0.00
0.00%
Por RegiãoUSD
Nome
Receita
Proporção
United States
667.43K
100.00%
Non-United States
0.00
0.00%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Sale of goods
667.43K
0.00%
Services
0.00
0.00%
Distribuição de ações
Atualizado em: dom, 20 de jul
Atualizado em: dom, 20 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Botgros (Vitalie)
27.68%
TII Jet Services, LDA
16.21%
Sheridan (Gareth)
15.79%
Glinka (Serguei)
7.40%
Melnik (Serguei)
7.36%
Other
25.57%
Investidores
Investidores
Proporção
Botgros (Vitalie)
27.68%
TII Jet Services, LDA
16.21%
Sheridan (Gareth)
15.79%
Glinka (Serguei)
7.40%
Melnik (Serguei)
7.36%
Other
25.57%
Tipos de investidores
Investidores
Proporção
Individual Investor
60.16%
Corporation
16.21%
Investment Advisor
2.09%
Investment Advisor/Hedge Fund
0.83%
Research Firm
0.12%
Other
20.59%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
44
8.86M
79.41%
+467.78K
2025Q1
43
8.13M
73.14%
+1.78M
2024Q4
40
8.04M
72.39%
+1.68M
2024Q3
40
8.08M
72.79%
+1.82M
2024Q2
38
5.19M
52.25%
+2.18M
2024Q1
34
4.36M
55.65%
+1.38M
2023Q4
30
4.30M
54.90%
+1.31M
2023Q3
29
2.96M
37.78%
-39.44K
2023Q2
28
2.95M
37.71%
-29.57K
2023Q1
28
2.96M
37.92%
-64.00
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Botgros (Vitalie)
3.09M
27.68%
+716.50K
+30.22%
Apr 25, 2025
TII Jet Services, LDA
1.81M
16.21%
+485.05K
+36.66%
Sep 01, 2024
Sheridan (Gareth)
1.76M
15.79%
-103.00
-0.01%
Apr 25, 2025
Glinka (Serguei)
825.00K
7.4%
--
--
Apr 25, 2025
Melnik (Serguei)
820.42K
7.36%
--
--
Apr 25, 2025
The Vanguard Group, Inc.
199.03K
1.78%
+74.44K
+59.75%
Mar 31, 2025
Goodman (Gerald)
86.33K
0.77%
--
--
Apr 25, 2025
Geode Capital Management, L.L.C.
63.55K
0.57%
+1.11K
+1.79%
Mar 31, 2025
Smith (Allan)
41.91K
0.38%
-6.99K
-14.29%
Apr 25, 2025
Patrick (Jeff)
36.61K
0.33%
--
--
Apr 25, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Jul 29, 2022
Split
6>7
Data
Tipo
Proporção
Jul 29, 2022
Split
6>7
